ArticleFrontiers in pharmacology2026
Transcriptomic and experimental identification of immune- and telomere-related genes in pelvic organ prolapse.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pelvic organ prolapse (POP) is a prevalent disease among women, and immune cell and telomere have potential associations with the pathogenesis of POP. The identification and validation of immune cell-related genes (ICRGs) and telomere-related genes (TRGs) in POP are of great significance for elucidating its mechanisms, screening diagnostic key genes, and identifying therapeutic targets. Methods: In this study, first, ICRGs were obtained based on immune infiltration and WGCNA; key genes related to immune cell and telomere in POP were identified from public-database transcriptome data through differential expression analysis, machine learning, expression level analysis and ROC analysis. Subsequently, a comprehensive analysis including nomogram construction, correlation analysis, GSEA, molecular regulatory network construction, and drug prediction explored the molecular mechanisms of these key genes in POP. Results: We identified 864 differentially expressed genes (DEGs), including 833 upregulated and 31 downregulated genes. The intersection of DEGs, telomere-related genes (TRGs), and immune cell-related genes (ICRGs) yielded six candidate genes. Machine learning further pinpointed CCNL1 and NAMPT as key biomarkers, which were significantly upregulated in POP samples (p < 0.05) and validated by RT-qPCR. Subsequently, a comprehensive analysis revealed their diagnostic potential via a nomogram (AUC: 0.847), a strong positive correlation (r = 0.78, p < 0.001), and enrichment in pathways such as ubiquitin-mediated proteolysis (GSEA). Molecular regulatory network construction predicted interactions with 21 key nodes and 28 interactions, and drug prediction identified 14 potential therapeutic compounds. These findings provide a theoretical basis for understanding POP pathogenesis and identifying novel therapeutic targets. Conclusion: This study identifies CCNL1 and NAMPT as novel immune- and telomere-related biomarkers for POP. These findings provide potential targets for diagnostic development and lay a computational foundation for future therapeutic strategies, although experimental validation is required to confirm their causal roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.